Aeterna Zentaris Inc. (NASDAQ:AEZS) Sees Significant Decline in Short Interest

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 4,100 shares, a drop of 75.7% from the April 15th total of 16,900 shares. Based on an average trading volume of 4,800 shares, the short-interest ratio is currently 0.9 days. Approximately 0.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Aeterna Zentaris in a report on Wednesday. They set a “sell” rating on the stock.

Aeterna Zentaris Stock Performance

Shares of NASDAQ:AEZS traded up $0.18 during trading on Friday, hitting $8.02. 9,851 shares of the stock were exchanged, compared to its average volume of 4,543. The company has a market capitalization of $9.74 million, a price-to-earnings ratio of -0.59 and a beta of 1.60. Aeterna Zentaris has a 1-year low of $5.44 and a 1-year high of $12.80. The company’s fifty day simple moving average is $8.06 and its 200-day simple moving average is $7.64.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($4.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.88) by ($0.76). Aeterna Zentaris had a negative return on equity of 63.20% and a negative net margin of 368.01%. The business had revenue of $0.12 million for the quarter.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.